{
    "nctId": "NCT01513408",
    "briefTitle": "Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy",
    "officialTitle": "Prospective Study of the Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as a New imMUne Prognostic Biomarker in Breast Cancer Treated by NEOadjuvant Chemotherapy",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 500,
    "primaryOutcomeMeasure": "Overall survival",
    "eligibilityCriteria": "inclusion criteria\n\n1. Signed informed consent\n2. Social security coverage\n3. Age between 18 and 80 years\n4. Histologically proven breast cancer, regardless of histological type or molecular subtype (triple negative, hormone-receptor positive, HER2+++), including inflammatory forms\n5. Localised breast cancer with or without axillary or subclavicular lymph node involvement\n6. Absence of bone or visceral metastasis on further evaluation (bone scintigraphy, chest X-ray, abdominal echocardiography or CT scan of the thorax, abdomen and pelvic area)\n7. Treatment by neoadjuvant chemotherapy (treatment protocol at physician's discretion)\n8. Patient amenable to receiving adjuvant therapy (chemotherapy, radiotherapy, hormone therapy, targeted therapy)\n9. Breast surgery (breast-sparing or not) planned after neoadjuvant chemotherapy\n\nexclusion criteria\n\n1. Metastatic breast cancer\n2. Neoadjuvant radiotherapy\n3. Patient not amenable to surgery\n4. Ongoing therapy for any other type of cancer\n5. Legal incapacity (incarceration or persons under legal guardianship)\n6. Patient unable to sign the informed consent or unable to attend medical follow-up for geographical, social or mental reasons.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}